Elranatamab in Relapsed/Refractory Multiple Myeloma

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Prior diagnosis of relapsed/refractory MM and have received 1 to 3 prior lines of therapy as defined by the IMWG criteria (Rajkumar et al., 2014) including anti-CD38 monoclonal antibody, proteosome inhibitor (PI), and immunomodulatory drug (IMiD), and BCMA-directed chimeric antigen receptor T-cell (CAR T-cell) therapy 1. Refractory is defined as having disease progression while on therapy or within 60 days of last dose in any line, regardless of response. 2. If participant has not received BCMA-directed CAR T-cell therapy, must be ineligible for CAR T-cell therapy or deferred such treatment by participant 4. Aged greater or equal to 18 years 5. Measurable disease as defined by any of the following: 1. Serum M-protein level ≥ 0.5 g/dL by serum protein electrophoresis (SPEP), or 2. Urine M-pro…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source